Samsung Bioepis said its sales in Europe reached $545.2 million last year, The Korea Herald reported Wednesday.
According to partner Biogen, sales of Benepali, Flixabi and Imradli jumped 44 percent year-over-year in the EU.
In particular, sales of Benepali climbed 31 percent to US$485.2 million, while revenue from Flixabi surged four-fold to $43.2 million.
Meanwhile, Imraldi generated $16.7 million after its launch last October.
FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>
To read more NewsPoints articles, click here.
